Previous 10 | Next 10 |
2023-05-06 01:58:52 ET Summary Like other anti-amyloid drugs, Eli Lilly's donanemab does not help APOE4 non-carriers. Donanemab does modestly slow down the progression of Alzheimer's disease during its early stages in APOE4 carriers but can cause brain bleeds and brain swelling, w...
2023-05-04 10:49:30 ET Ionis Pharmaceuticals ( NASDAQ: IONS ) traded flat on Thursday after Citi upgraded the developer of RNA-targeted therapeutics to Neutral from Sell following the company's better-than-expected Q1 2023 results. Carlsbad, California-based biotech reported...
2023-05-03 22:35:00 ET Summary Eli Lilly made headlines this morning with an announcement that their anti-amyloid antibody donanemab hit its endpoints in a Phase III clinical trial. The natural comparison is with lecanemab (Leqembi), the recently approved antibody from Eisai and B...
2023-05-03 15:37:28 ET Eli Lilly ( NYSE: LLY ) added ~7% to reach a new 52-week high Wednesday after the company reported early Phase 3 data for its anti-amyloid agent donanemab in Alzheimer's disease, sparking sharp gains among rival drug developers. Notable gainers include...
2023-05-03 07:13:53 ET Eli Lilly's ( NYSE: LLY ) Alzheimer's drug donanemab met the main and secondary goals of a phase 3 trial as the drug slowed cognitive and functional decline in people with early symptomatic Alzheimer's disease (AD). Lilly expects to fil...
2023-05-03 04:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-05-02 11:37:13 ET Biogen has set a price for its recently approved ALS therapy Qalsody (tofersen) at $14,230 per dose. Given that 14 doses are required in the first year of treatment, that comes out to just under $200K for the first year alone, Endpoints News reported...
2023-05-01 08:47:05 ET After three straight sessions of gains, Biogen ( NASDAQ: BIIB ) shares continued to rise in the pre-market Monday as Guggenheim upgraded the biotech citing full FDA approval for its Alzheimer's therapy Leqembi developed with Eisai ( OTCPK:ESALF )( OTCPK:...
2023-05-01 08:33:59 ET A stronger-than expected earnings season is bolstering belief that an EPS recovery can arrive in the second half of the year, but at the same time leading macro data have slowed, according to Morgan Stanley strategist Mike Wilson. Late last week, concerns about ...
2023-04-28 10:54:53 ET The following slide deck was published by Biogen Inc. in conjunction with their 2023 Q1 earnings call. For further details see: Biogen Inc. 2023 Q1 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases ...
TOKYO and CAMBRIDGE, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today tha...
NEW YORK, NY / ACCESSWIRE / June 12, 2024 / Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq:BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting ...